Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro s… [+4601 chars]Read More
Eli Lilly blows past quarterly estimates posts strong outlook as Zepbound and Mounjaro sales soar CNBC
